Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-12-17 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于长春百克生物科技股份公司首次公开发行网下配售限售股上市流通的核查意见
Share Issue/Capital Change Classification · 95% confidence The document is a detailed official statement from CITIC Securities regarding the verification opinion on the listing and circulation of restricted shares from the initial public offering (IPO) offline allotment of Changchun Baike Biotechnology Co., Ltd. It references regulatory approvals, specific share quantities, lock-up periods, shareholder commitments, and detailed shareholder lists with shareholding proportions. The content focuses on the release and circulation of restricted shares post-IPO, which is a capital market event related to share issuance and capital structure changes. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a voting result, management change, or legal proceeding. The document is substantive and lengthy (15,000 characters), not a brief announcement or certification. Therefore, the classification best fitting this document is a Share Issue/Capital Change (SHA) filing, as it concerns the listing and circulation of restricted shares following an IPO allotment.
2021-12-17 Chinese
长春百克生物科技股份公司首次公开发行网下配售限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO). It includes specifics about the number of shares, lock-up periods, shareholder commitments, regulatory approvals, and a comprehensive list of shareholders with restricted shares now becoming tradable. The document references regulatory approvals from the China Securities Regulatory Commission and compliance with relevant laws and stock exchange rules. It is not a financial report, earnings release, or management discussion but rather an official announcement about the unlocking and listing of restricted shares for trading. This fits the category of a Share Issue/Capital Change announcement, as it deals with changes in share capital availability and circulation status.
2021-12-17 Chinese
长春百克生物科技股份公司2021年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2021 third extraordinary shareholders meeting (临时股东大会会议资料) of Changchun Baike Biotechnology Co., Ltd. It contains detailed meeting notices, agenda, and multiple proposals for shareholder voting, including appointment of the 2021 financial audit firm, board of directors re-election, and supervisory board re-election. The content is focused on the meeting procedures, candidate profiles for board and supervisory positions, and voting instructions. There is no financial statement or earnings data presented, nor is it a transcript or announcement of results. The document is clearly the meeting materials provided to shareholders for the Extraordinary General Meeting (EGM). This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. The document length is substantial (15,000 characters), and it is not merely an announcement or notice of a report publication. Therefore, the correct classification is AGM Information (AGM-R).
2021-12-17 Chinese
独立董事提名人声明（付百年）
Board/Management Information Classification · 100% confidence The document is a statement nominating an independent director candidate for the company's board. It details the qualifications, independence criteria, and compliance with regulatory requirements for the nominee. There are no financial statements, earnings data, or report attachments. The content is focused on board/management information, specifically about director nomination. The document length is short (1565 characters), and it is not an announcement of a report publication or a certification. Therefore, the appropriate classification is Board/Management Information (MANG).
2021-12-09 Chinese
长春百克生物科技股份公司第四届董事会独立董事关于第四届董事会第二十次会议相关事项的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors providing their prior approval opinion on the appointment of the company's 2021 financial audit and internal control audit firm. It references the appointment of an audit firm for a specific fiscal year but does not contain any actual audit report, financial statements, or detailed audit results. The document is short (581 characters) and serves as an official opinion or approval related to audit matters rather than the audit report itself. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit reports and related audit information excluding full annual reports.
2021-12-09 Chinese
独立董事提名人声明（徐大勇）
Board/Management Information Classification · 95% confidence The document is a statement from the nominating party regarding the nomination of an independent director candidate for the company's board. It details the qualifications, independence criteria, and compliance with regulatory requirements for the nominee. There is no financial data, no report attached or referenced as published, and no mention of voting results or meeting materials. This is a governance-related announcement about board composition and director nomination, fitting the category of Board/Management Information (MANG). The document length is short and focused solely on director nomination, confirming it is not a full report or regulatory filing but a management/board information announcement.
2021-12-09 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.